
Product Information

Size:

50ul

Reactivity:

Human

Source:

Rabbit

Isotype:

IgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:2000-1:5000, WB:1:500-1:2000,
IHC:1:50-1:200

Protein Background:

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to proinflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis.

Gene ID:

KLRF1

Uniprot

Q9NZS2

Synonyms:

killer cell lectin-like receptor subfamily F, member 1


Immunogen:

Synthetic peptide of human KLRF1.


Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol


Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using PACO19914(KLRF1 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).



Gel: 10%SDS-PAGE, Lysate: 40 μ g, Lane: Human bladder carcinoma tissue, Primary antibody: PACO19914(KLRF1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO19914(KLRF1 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).